Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Option Exercises and Sales Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, executed stock option exercises and sales of common stock on February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 24, 2025, Michael Benkowitz, the President and COO of United Therapeutics, engaged in transactions involving the company's stock.
• These transactions included the exercise of stock options and the subsequent sale of common stock.
• The exercises and sales were conducted under a Rule 10b5-1 trading plan established on August 7, 2024.
• The transactions involved multiple sales at varying prices, with weighted average prices reported for each set of trades.
• Some of the shares are held in a trust where Benkowitz and his spouse are co-trustees, while others are held in a trust for family members where Benkowitz has sole investment and voting power.
• Benkowitz has indirect beneficial ownership of some shares through trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by an executive under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or a security holder of the issuer.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of acting on non-public information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The use of a 10b5-1 trading plan is a common and accepted method for corporate insiders to manage their stock holdings while avoiding potential insider trading accusations.
• Comparable companies such as Amgen, Biogen, and Gilead Sciences also have frequent Form 4 filings related to executive stock options and sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates